Loading…
VolitionRx Limited is projected to decline to $1.16 by 2027, a -14% move from its current price of $1.35. VNRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.29 | $1.35 | $1.42 | +0.03% |
| Jul 14 | $1.26 | $1.35 | $1.45 | +0.05% |
| Jul 15 | $1.24 | $1.35 | $1.47 | +0.08% |
| Jul 16 | $1.23 | $1.35 | $1.49 | +0.10% |
| Jul 17 | $1.21 | $1.35 | $1.51 | +0.13% |
| Jul 18 | $1.20 | $1.35 | $1.52 | +0.16% |
| Jul 19 | $1.19 | $1.35 | $1.54 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.35 | $1.54 | +0.18% |
| Week 2 | $1.13 | $1.35 | $1.62 | +0.36% |
| Week 3 | $1.09 | $1.36 | $1.69 | +0.55% |
| Week 4 | $1.05 | $1.36 | $1.76 | +0.73% |
| Week 5 | $1.02 | $1.36 | $1.81 | +0.91% |
| Week 6 | $0.998 | $1.36 | $1.87 | +1.10% |
| Week 7 | $0.9751 | $1.37 | $1.92 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
VolitionRx Limited is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis, in the United States, Europe, and Asia.
The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, which detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
VolitionRx Limited is headquartered in Henderson, Nevada.
VolitionRx Limited (VNRX) is a healthcare company focused on epigenetics, with a current price of $1.42 and a market cap of $16.93M. It ranks 4703 in market cap.
The 2026 forecast shows an average price of $1.42 with a 0 in ROI and NEUTRAL sentiment.
Longer-term forecasts show potential upside beyond 2030: 2030 average is $1.43 with ROI 0.9; 2040 average is $2.02 with ROI 42.1; and 2050 average is $4.49 with ROI 216, suggesting substantial upside potential if the path plays out.
A major floor 89.4% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 113.3% above — a clean break opens room to run.
A major ceiling 211.1% above — clearing it would confirm fresh momentum.
Key VNRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VNRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.36 | Sell | $1.35 | Sell |
| MA 10 | $1.36 | Sell | $1.36 | Sell |
| MA 20 | $1.36 | Sell | $1.46 | Sell |
| MA 50 | $1.94 | Sell | $1.97 | Sell |
| MA 100 | $2.84 | Sell | $2.95 | Sell |
| MA 200 | $5.06 | Sell | $4.91 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.24 | Neutral |
| Stoch RSI (14) | 87.71 | Sell |
| CCI (20) | -10.31 | Neutral |
| Williams %R (14) | -33.33 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | 11.57 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 66.67 | Neutral |
| TRIX (15) | -1.89 | Sell |
| Awesome (5,34) | -0.39 | Sell |
| Ultimate (7,14,28) | 44.56 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.35 | Buy |
| ADX (14) | 29.76 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 40. The 50-day simple moving average is $2.21 and the 200-day simple moving average is $5.51.
Support is listed at $1.21 and resistance at $3.13, defining a directional band for near-term price action.
The 30-day price range spans from a low of $0.964 to a high of $2.09.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.21 | $1.35 | $1.85 | 0% | Neutral | |
| $0.8558 | $1.16 | $1.69 | -14% | Neutral | |
| $0.8256 | $1.18 | $1.82 | -13% | Neutral | |
| $0.7859 | $1.17 | $1.90 | -13% | Neutral | |
| $0.8691 | $1.35 | $2.27 | 0% | Neutral | |
| $1.05 | $1.70 | $2.95 | +26% | Bullish | |
| $0.9339 | $1.57 | $2.80 | +16% | Neutral | |
| $0.8957 | $1.56 | $2.85 | +15% | Neutral | |
| $0.8843 | $1.59 | $2.98 | +18% | Neutral | |
| $0.6745 | $1.25 | $2.40 | -7% | Neutral | |
| $0.9136 | $1.98 | $4.16 | +47% | Bullish | |
| $1.91 | $4.23 | $9.74 | +214% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.21 | $1.35 | $1.70 | +0.00% |
| August 2026 | $1.14 | $1.38 | $1.72 | +1.95% |
| September 2026 | $1.13 | $1.38 | $1.76 | +0.43% |
| October 2026 | $1.19 | $1.47 | $1.90 | +6.15% |
| November 2026 | $1.18 | $1.47 | $1.94 | +0.49% |
| December 2026 | $1.11 | $1.39 | $1.85 | -5.72% |
Click any year to see its month-by-month VNRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VNRX is projected to trade between $1.21 and $1.85, averaging $1.35 — a potential gain of 0% from today's $1.35. A consolidation phase looks the most probable path here.
VolitionRx Limited's 2027 outlook centres on $1.16, within a $0.8558 to $1.69 range. That is -14% versus the projected 2026 average. That marks a -14% change versus current levels. Price action looks broadly range-bound.
By 2028, VNRX could reach as high as $1.82, with a base case around $1.18 and support toward $0.8256 — roughly -13% from $1.35. A consolidation phase looks the most probable path here.
Expect VNRX to range from $0.7859 to $1.90 through 2029. The $1.17 average target implies a -13% move from current prices. That is 0% versus the projected 2028 average. Price action looks broadly range-bound.
The VNRX price prediction for 2030 points to an average of $1.35 (low $0.8691, high $2.27) — a potential gain of 0% on today's $1.35. A consolidation phase looks the most probable path here.
In 2031, VNRX is projected to trade between $1.05 and $2.95, averaging $1.70 — a potential gain of +26% from today's $1.35. That is up +26% on the projected 2030 average. Momentum favours further upside here.
VolitionRx Limited's 2032 outlook centres on $1.57, within a $0.9339 to $2.80 range. That is -8% versus the projected 2031 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, VNRX could reach as high as $2.85, with a base case around $1.56 and support toward $0.8957 — roughly +15% from $1.35. Price action looks broadly range-bound.
Expect VNRX to range from $0.8843 to $2.98 through 2034. The $1.59 average target implies a +18% move from current prices. That is up +2% on the projected 2033 average. A consolidation phase looks the most probable path here.
The VNRX price prediction for 2035 points to an average of $1.25 (low $0.6745, high $2.40) — a potential decline of -7% on today's $1.35. Price action looks broadly range-bound.
In 2040, VNRX is projected to trade between $0.9136 and $4.16, averaging $1.98 — a potential gain of +47% from today's $1.35. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
VolitionRx Limited's 2050 outlook centres on $4.23, within a $1.91 to $9.74 range. That is up +113% on the projected 2040 average. That marks a +214% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VNRX today (≈ 740.740741 VNRX) could be worth
$3,136.29
+$2,136.29 (+214%) by 2050 · US Dollar
Based on the average projected VNRX price of $4.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VNRXwould be worth at today's price.
$1,000 invested in VNRX on Jul 10, 2025 (≈ 73.52941 VNRX) would be worth
$99.26
-$900.74 (-90.1%) today · 0.10× · US Dollar
Based on a VNRX entry price of $13.6 vs. today's $1.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.4 | $964.29 | -3.6% |
| 1 month ago | $1.39 | $971.22 | -2.9% |
| 3 months ago | $3.4 | $397.06 | -60.3% |
| 6 months ago | $6.8 | $198.53 | -80.1% |
| 1 year ago | $13.6 | $99.26 | -90.1% |
| All time (5.0y) ago | $63 | $21.43 | -97.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VNRX forecast.
Our base-case forecast reaches $2.70 around 2050.
Implied market cap at $2.70: $32.19M
In the multi-year forecast, 2030 shows an average of $1.43 with ROI 0.9, followed by 2031 at $1.78 average with ROI 25.4, and 2032 at $1.65 average with ROI 16.5. The forecast remains neutral through 2033–2034 with average values around $1.60–$1.65 and modest positive ROI.
The forecast turns more bullish by 2040, with an average of $2.02 and ROI 42.1, and reaches for 2050 with an average of $4.49 and ROI 216.
Bearish years appear in the near term, notably 2027 with avg $1.21 (ROI -14.8) and 2028 with avg $1.18 (ROI -17.2), followed by 2029 with avg $1.20 (ROI -15.8). These ranges illustrate the high volatility around the asset’s price path. These are estimates and not guarantees, reflecting uncertainty and market sensitivity to evolving conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.43, with a min of $0.8842 and a max of $2.49, and a forecasted ROI of 0.9; sentiment is NEUTRAL.
The forecast depicts mixed near-term performance, including bearish years in 2027–2029 (negative ROI), but also upside potential later, with 2040 ROI of 42.1 and 2050 ROI of 216. The decision depends on risk tolerance and time horizon.
Yes—the maximum forecast price by 2050 is $10.32.
Current price is $1.42 and market cap is $16.93M.
The 2026 forecast has an average price of $1.42, a min of $1.21, a max of $1.96, with ROI 0 and sentiment NEUTRAL.
VolitionRx Limited Community Discussion
0Share your VolitionRx Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.